FDA kicks off review of second kidney cancer combo based on ...

Bristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy that will help defend its first-line kidney cancer franchise.

Exelixis doubles down on ADCs for cancer with NBE, Catalent ...

Exelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug conjugates reinforces a recent change of direction for the biotech.

BMS gets an important win for Opdivo combination in kidney c...

Exelixis' Cabometyx approved in second-line liver cancer in ...

Exelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a second line therapy option for patients previously treated with Bayer’s Nexavar.<

Ipsen/Exelixis' drug approved in EU for kidney cancer

Cabometyx secures new indication in renal cell carcinoma.